 Shares of EyePoint Pharmaceuticals NASDAQ:EYPT moved lower by 2.5 in pre-market trading after the company reported Q4 results.Quarterly Results Earnings per share increased 9.09 year over year to 0.10, which were in line with the estimate of 0.10.Revenue of 4,122,000 decreased by 42.83 from the same period last year, which beat the estimate of 3,730,000.Looking Ahead Earnings guidance hasnt been issued by the company for now.Revenue guidance hasnt been issued by the company for now.Conference Call Details Date: Aug 05, 2020View more earnings on EYPTTime: 08:30 AMET Webcast URL: 52-week high: 2.6952-week low: 0.66Price action over last quarter: down 13.34Company Overview EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed 5 FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.See more from Benzinga Stocks That Hit 52-Week Lows On FridayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 